Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK: Reinvestment-linked PBC (practice-based commissioning) only slightly off target:

This article was originally published in Clinica

Executive Summary

Implementation in England of practice-based commissioning (PBC) arrangements, which feature incentives to develop new services, is only slightly behind schedule, but there is still some way to go to meet the completion target set for the end of 2006. At the end of June, 120 of England's 303 PCTs (40%, against a target of 45%) met the criterion "trajectory" related to PBC implementation, according to figures released today. This is up on May, which stood at 82 PCTs (27%, against a target of 29%). A major incentive of the PBC regime is that the "profits" from service provision can be retained for reinvestment specifically in facilities and equipment. "The planned trajectories must reach 100% by December," the Department of Health notes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel